

CLINICAL AND ECONOMIC IMPACT OF INFLIXIMAB BIOSIMILAR INFLECTRA IN RHEUMATOID ARTHRITIS, PSORIATIC ARTHROPATHY AND ANKYLOSING SPONDYLITIS NAÏVE AND SWITCHED PATIENTS: AFTER 5 YEARS OF FOLLOW-UP

Joaquín Borrás-Blasco¹, Antonio Gracia-Pérez², Alejandro Valcuende Rosique, D. Elvira Casterá¹, J. Dolores Rosique-Robles¹, F. Javier Abad¹

¹Pharmacy Service ²Rheumatology Section, Hospital de Sagunto, Avda. Ramon y Cajal s/n, Sagunto, Valencia, Spain

BACKGROUND

Biosimilar Inflectra® has been authorized by the EMA for Rheumatoid Arthritis (RA), Psoriatic Arthritis (PSA) and Ankylosing Spondylitis (AS).

OBJECTIVES

Determine the persistence, clinic and economic impact of the use of Inflectra® in RA, PSA and AS naïve and Remicade® switched patients.



Figure 1. Remicade® and Inflectra® drugs.

METHODS

Patients treated with Inflectra® for more than 6 months: we collected age, sex, indication, dose, safety and persistence of Inflectra® naïve patients.

In Remicade® switched patients: we collected persistence before to the switching to Inflectra®. Efficacy endpoints included DAS28 and BASDAI.

We determined the real cost of Inflectra® treatment for each patient from individualized IV administration and correlated dates during the study period were collected from FARMIST/DISPENSA.

We simulated the real cost of these patients as if they have received Remicade®.




Figure 2. Naïve and Switched patients.

RESULTS

From Jun 2015 to Sept 2019 a total of 62 patients 31 AS, 18 RA, 13 PSA were treated with Inflectra®. 33 (53%) patients were naïve patients and 29 (47%) were Remicade® pretreated patients.

At Sept 2019, 33 (54%) patients continued on Inflectra® treatment (11 naïve patients and 22 Remicade® pretreated patients) in clinical remission.

29 patients discontinued therapy: 24 due to relapse of their rheumatology condition. 5 patients due to adverse reactions.

TABLE 1	PERSISTENCE (months)		
	AS	RA	PSA
Inflectra Patients	24.4±7.4	19.2±5.4	31.7±6.7
Naïve Patients	19.1±4.4	13.8±3.2	24.5±10.4
Remicade Pretreated Patients	29.7±5.8	24.6±7.2	37.9±8.1

Table 1. Persistence in studied patients.

CONCLUSION

The implementation of the procedure to use Inflectra® for all prescriptions of Infliximab® in these patients saved 197,964€ during 5 years.




Figure 3. Costs due to the use of Remicade® and Inflectra® during 5 years

At a time when therapy cost is an unavoidable component of health-care treatment decisions, Inflectra could be a cost-effective option for selected RA, PSA and AS patients.

